PET/MRI in Rectal Cancer

PET/MRI in Rectal Cancer is a phase 2, interventional study registered as NCT06057831 by AHS Cancer Control Alberta, with a registry enrolment figure of 40 participants, started 2026-05 and due to reach its primary completion in 2029-05. Interventions recorded: Total Neo-adjuvant Therapy; 18FDG-PET/MRI scan. Conditions listed: Rectal Cancer. Primary outcome: The primary endpoint of the study is pathological response (pCR) prediction with PET/MRI.; Correlation between PET/MRI reported pCR and complete(pCR) or incomplete response(non-pCR) to total neoadjuvant therapy determined by final pathology will be defined.. Colorectal eligibility wording from the registry: "Patients with histologically proven adenocarcinoma of the rectum". No results are recorded here; the registry entry is the source.